Florbetapir PET may predict cognitive decline, Alzheimer’s conversion

October 18, 2012

Individuals at risk for progressive cognitive decline who had amyloid-positive florbetapir PET results performed worse on cognitive assessments and were more likely to convert to Alzheimer’s disease (AD) within 18 months than those with amyloid-negative results, according to a study published Oct. 16 in Neurology.